BeiGene Ltd ADR BGNE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BGNE is a good fit for your portfolio.
News
-
BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024
-
BeiGene to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
-
BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS™ First in Human Study
-
BRUKINSA® Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL
-
BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024
-
BeiGene Reports First Quarter 2024 Financial Results and Business Updates
-
BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report
-
Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting
Trading Information
- Previous Close Price
- $147.98
- Day Range
- $145.53–149.00
- 52-Week Range
- $126.97–225.23
- Bid/Ask
- $146.81 / $147.52
- Market Cap
- $15.56 Bil
- Volume/Avg
- 88,432 / 187,615
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 5.56
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
BeiGene Ltd is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. BeiGene’s key cancer treatments are BRUKINSA (zanubrutinib), Bruton's tyrosine kinase (BTK) inhibitor, and TEVIMBRA (tislelizumab), an anti-PD-1 antibody. In addition, it has a diverse pipeline of novel therapeutics focusing on a range of malignancies, including AML, MDS, multiple myeloma, lung, gastrointestinal, breast, and gynecologic cancers. The Company operates in one segment: pharmaceutical products and is primarily located in the U.S. and the PRC. Key revenue is generated from the U.S.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Large Core
- Total Number of Employees
- 10,000
- Website
- https://www.beigene.com
Comparables
Valuation
|
Metric
|
BGNE
|
09939
|
06978
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 4.57 | 0.92 | — |
Price/Sales | 5.56 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BGNE
|
09939
|
06978
|
|---|---|---|---|
Quick Ratio | 1.73 | 2.07 | 1.02 |
Current Ratio | 2.08 | 2.10 | 1.05 |
Interest Coverage | — | −110.66 | −38.73 |
Quick Ratio
BGNE
09939
06978
Profitability
|
Metric
|
BGNE
|
09939
|
06978
|
|---|---|---|---|
Return on Assets (Normalized) | −7.03% | −64.88% | −24.88% |
Return on Equity (Normalized) | −10.84% | −97.47% | −103.89% |
Return on Invested Capital (Normalized) | −10.66% | −75.42% | −31.45% |
Return on Assets
BGNE
09939
06978
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Vtkmrqsx | Chz | $628.7 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Zylqqvmml | Wfhhz | $122.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Hskhqnxp | Lcvvcd | $114.0 Bil | |||
| Moderna Inc
MRNA
| Dqmgqsdy | Wggjc | $45.3 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Tjjbcmjw | Ddxxyxd | $31.8 Bil | |||
| argenx SE ADR
ARGX
| Bjpyjdxd | Lvs | $25.9 Bil | |||
| BioNTech SE ADR
BNTX
| Rclltqp | Nxm | $19.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Nfgmpzyn | Sfkzb | $15.5 Bil | |||
| United Therapeutics Corp
UTHR
| Wcsmrwnqj | Yxf | $14.0 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Tjgyrdzkg | Vsgxrxn | $11.6 Bil |